Myocardial Infarction Treatment Market is valued at USD 1524.5 Million in 2020 and is expected to reach USD 2353.5 Million by 2027 with a CAGR of 6.4% over the forecast period.
Global Myocardial Infarction Treatment Market: Global Size, Trends, Competitive, Historical & Forecast Analysis, 2021-2027- Rising incidences of cardiovascular diseases, and increasing prevalence of hypertension, obesity, diabetes, and others are the major factors driving the growth of Global Myocardial Infarction Treatment Market.
Myocardial Infarction is generally known as a heart attack. It is an irreversible acute medical situation, which precedes the necrosis of heart muscles secondary to prolonged ischemia. This happens when blood flow reduces or stops to a part of the heart, affecting damage to the heart muscle. It is caused by the blockage in the supply of oxygen-rich blood to heart muscles, causing lasting heart muscle injury as well as the death of cells. The blockage is because of atherosclerosis, a procedure in which the plaque (fatty patches) is developed on the inner sidewall of the coronary artery or one of its lesser branches. If the plaque is cracked or ruptured, the blood clot is created inside the artery preventing the blood flow. In most cases, myocardial infarctions are situated in the posterior, septal, anterior, lateral, or inferior walls of the left ventricle of the heart. Thus, lack of oxygen triggers distinct pain in the chest and death of myocardial tissue, which indicates myocardial infarction in humans.
Myocardial Infarctions are of three types which are ST-segment elevation myocardial infarction (STEMI), non-ST segment elevation myocardial infarction (NSTEMI), and Silent heart attack. Such diseases can be diagnosed by chest x-ray, CT scan, electrocardiography, echocardiography, blood test, and another diagnostic test. Moreover, the heart attack can be cured by numerous medications including antiplatelet agents, aspirin thrombolytic, and other medicines and some surgical processes comprising angioplasty bypass surgery, heart transplant, and so on. Certain devices used for the treatment of myocardial infarction are pacemakers, left ventricular assist devices, and implantable cardioverter-defibrillator. In 1879, the pathologist Ludvig Hektoen determined that myocardial infarction was produced by coronary thrombosis secondary to sclerotic alterations in the coronaries.
Contrary to the projected surge in myocardial infarction (MI) associated with the novel coronavirus, there have been reports that the COVID‐19 pandemic has knowingly reduced the number of activations for ST‐elevation myocardial infarction (STEMI) in most cities with the devastating spread of COVID‐19 cases. And a survey showed that the COVID-19 pandemic significantly affected the heart-healthy lifestyle and anxiety levels of patients with a history of premature MI who were already in regular follow-up in a tertiary out-patient prevention clinic before the pandemic. Thus, the pandemic has enhanced the sale of drugs and eventually the growth of the myocardial infarction treatment market in the forecast period.
The regions covered in the Myocardial Infarction treatment market report are North America, Europe, Asia-Pacific, and the Rest of the World. Based on a country level, the market of myocardial infarction treatment is subdivided into the U.S., Mexico, Canada, U.K., France, Germany, Italy, China, Japan, India, Southeast Asia, Middle East Asia (UAE, Saudi Arabia, Egypt) GCC, Africa, etc.
Global myocardial infarction treatment market reports cover prominent players like Nortech Systems, Inc., Tecomet, Inc., Celestica Inc., Heraeus Holding, Flextronics International Ltd., Integer Holdings Corporation, Plexus Corp., West Pharmaceutical Services, Inc., Sanmina Corporation, and others.
The global myocardial infarction treatment market is segmented on the basis of product type, distribution channel, and region & country level. Based on product type, the myocardial infarction market is classified as Antiplatelet agents, Glycoprotein IIb/IIIa inhibitors, antithrombotic agents, beta-adrenergic blockers, vasodilators, angiotensin-converting enzyme (ACE) inhibitors, angiotensin-receptor blockers, analgesics, and thrombolytics. Based on the distribution channel, the market is categorized as hospitals, hospitals pharmacies, drug stores, and online drug stores.
Rising incidences of cardiovascular diseases (CVDs), increasing incidences of coronary artery disease, and changes in lifestyle are some of the major factors driving the growth of the myocardial infarction treatment market. Cardiovascular diseases are conditions that affect the function of the heart such as Heart failure, congenital heart disease, Pericardial disease, Heart attack, and many hearts related diseases. Cardiovascular diseases are increasing all over the world owing to high blood pressure, smoking, diabetes, and so on. For example; according to the Centers for Disease Control and Prevention (CDC), approximately 655,000 people in the U.S. die of heart disease annually. One person dies every 36 seconds in the United States from cardiovascular disease. Also, according to Eurostat 2020, Also, around 3.9 million people die of cardiovascular disease in Europe every year, and cardiovascular disease accounts for almost 45% of all deaths in Europe.
In addition, the growing number of smokers, increasing cases of obesity, diabetes, hypertension, and others are also fostering the market growth. For example, according to the World Health Organization 2020, smoking kills more than 8 million people each year. Secondhand smoking triggers more than 1.2 million premature deaths per year and results in severe cardiovascular diseases. Smoking increases the risk of heart diseases. Therefore, the rise in the number of smokers is also supplementing the growth of the global myocardial infarction treatment Market. However, the rise in overall healthcare expenditure and high rates of clinical trials are some of the market-limiting factors that may hamper the growth of the myocardial infarction market in the forecast period. In spite of that, the surge in acceptance of newer treatment technologies by developing nations and technology advances are likely to create new avenues for the myocardial infarction market in the coming future.
Geographically, North America is expected to dominate the global myocardial infarction treatment market due to various factors such as the rising number of patients with CVDs and an increasing number of cases of obesity, hypertension, and others in this region. Foe example; Cardiovascular disease (CVD), listed as the underlying cause of death, accounted for 868,662 deaths in the U.S. in 2017. Heart Disease remains the number one cause of death in the US, according to 2018 data. Hypertension prevalence is higher among people in the United States. For example, the prevalence of hypertension was 45.4% among adults and was higher amongst men (51.0%) and in women (39.7%). Overall hypertension prevalence was increased to 45.4% in 2018 in U.S. Hypertension is a major risk factor for cardiovascular disease which leads to several severe heart-related diseases. Likewise, according to Healthline 2020, around 36.5 percent of people are obese in the United States, Obesity increases the risks of dozens of diseases like heart disease, stroke, cancer, and many others.
The Asia Pacific is expected to witness the fastest growth in the global myocardial infarction treatment market within the forecast period owing to the increasing geriatric population, along with lifestyle changes, and increasing prevalence of diabetes in this region. People aged 65 and more are much more likely to endure a heart attack, to have a stroke, or to develop coronary heart disease, heart failure. For instance; according to the Global data, in China, the elderly population in cities has increased to 11% in 2018. China is the country with the greatest number of diabetics worldwide, with around 116 million people were suffering from diabetics. The aged population and diabetics lead to increasing the risks like heart attack, heart failure, and myocardial infarction.
|Historical data||2015 - 2020|
|Forecast Period||2021 - 2027|
|Market Size in 2020:||USD 1524.5 Million|
|Base year considered||2020|
|Forecast Period CAGR %:||
|Market Size Expected in 2027:||USD 2353.5 Million|
|Tables, Charts & Figures:||175|
|Myocardial Infarction Treatment Companies:||Nortech Systems, Inc., Tecomet, Inc., Celestica Inc., Heraeus Holding, Flextronics International Ltd., Integer Holdings Corporation, Plexus Corp., West Pharmaceutical Services, Inc., Sanmina Corporation, and others|
|Segments Covered||By Product Type, By Distribution Channel|
|Regional Analysis||North America, U.S., Mexico, Canada, Europe, UK, France, Germany, Italy, Asia Pacific, China, Japan, India, Southeast Asia, South America, Brazil, Argentina, Columbia, The Middle East and Africa, GCC, Africa, Rest of the Middle East and Africa|
Middle East and Africa
We are always looking to hire talented individuals with equal and extraordinary proportions of industry expertise, problem solving ability and inclination interested? please email us firstname.lastname@example.orgJOIN US
BrandEssence® Market Research and Consulting Pvt ltd.
Kemp House, 152 - 160 City Road, London EC1V 2NX
© Copyright 2022-23 BrandEssence® Market Research and Consulting Pvt ltd. All Rights Reserved | Designed by BrandEssence®